News
Why Corcept Therapeutics Incorporated Stock Surged Higher Today
Shares of the rare-disease specialist Corcept Therapeutics Incorporated (NASDAQ: CORT) rose by 8.78% on heavy volume today, due to a stronger-than-expected second-quarter earnings report
3 Exciting Biotechs Under $30: Novocure Is Revolutionizing Brain Cancer Treatment
Novocure (NASDAQ: NVCR) is the company behind TTFields, a revolutionary new and nontoxic treatment for glioblastoma that uses low-intensity, alternating electrical fields to impede cancerous cell
Here's What Pushed ImmunoGen, Inc. Stock 16.5% Lower in July
Shares of ImmunoGen, Inc. (NASDAQ: IMGN), an oncology-focused biotech, dipped 16.5% lower in July according to data from S&P Global Market Intelligence. A fairly benign earnings report near the end of
10 Reasons Illumina's Momentum Is Just Cranking Up
Illumina (NASDAQ: ILMN) knocked the ball out of the park with its second-quarter earnings results. Shares soared after the gene-sequencing pioneer blew away expectations for revenue and earnings
10 Reasons Illumina's Momentum Is Just Cranking Up
Illumina (NASDAQ: ILMN) knocked the ball out of the park with its second-quarter earnings results. Shares soared after the gene-sequencing pioneer blew away expectations for revenue and earnings
10 Reasons Illumina's Momentum Is Just Cranking Up
Illumina (NASDAQ: ILMN) knocked the ball out of the park with its second-quarter earnings results. Shares soared after the gene-sequencing pioneer blew away expectations for revenue and earnings
3 Exciting Biotechs Under $30: Flexion Therapeutics' Response to the Opioid Epidemic
The opioid epidemic is a huge and tragic problem, and the market is starved for solutions. Flexion Therapeutics (NASDAQ: FLXN) is one company that's working on filling that gap and is close to
Here's Why Spark Therapeutics Inc. Is Soaring Today
After reporting second-quarter results that contained upbeat clinical news, Spark Therapeutics (NASDAQ: ONCE), a clinical-stage company focused on gene therapy, rose 18% as of 12:30 p.m. EDT on
IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth
IDEXX Laboratories (NASDAQ: IDXX) reported solid revenue growth with operating income and earnings growing even faster allowing the animal diagnostic company to raise 2017 guidance.But investors
IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth
IDEXX Laboratories (NASDAQ: IDXX) reported solid revenue growth with operating income and earnings growing even faster allowing the animal diagnostic company to raise 2017 guidance.But investors
IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth
IDEXX Laboratories (NASDAQ: IDXX) reported solid revenue growth with operating income and earnings growing even faster allowing the animal diagnostic company to raise 2017 guidance.But investors
Here's Why Amarin Corporation plc Is on the Rise Today
Shares of Amarin Corporation plc (NASDAQ: AMRN), a cardiovascular health-focused biotech, popped 12.9% higher this morning after reporting second-quarter earnings. Investors cheered the
Illumina Soars After Crushing Expectations for Q2
In response an upbeat second-quarter report and bullish guidance, shares of Illumina (NASDAQ: ILMN), a leading provider of genetic testing equipment, rose Wednesday morning. The stock was up by 13.3%
Illumina Soars After Crushing Expectations for Q2
In response an upbeat second-quarter report and bullish guidance, shares of Illumina (NASDAQ: ILMN), a leading provider of genetic testing equipment, rose Wednesday morning. The stock was up by 13.3%
Illumina Soars After Crushing Expectations for Q2
In response an upbeat second-quarter report and bullish guidance, shares of Illumina (NASDAQ: ILMN), a leading provider of genetic testing equipment, rose Wednesday morning. The stock was up by 13.3%
A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus
A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus
3 Companies Building the World of Tomorrow
It's always intriguing to think about what new technologies the future will bring. But what you might not realize is that many of the building blocks of tomorrow are already in place. And lucky for
3 Companies Building the World of Tomorrow
It's always intriguing to think about what new technologies the future will bring. But what you might not realize is that many of the building blocks of tomorrow are already in place. And lucky for
3 Companies Building the World of Tomorrow
It's always intriguing to think about what new technologies the future will bring. But what you might not realize is that many of the building blocks of tomorrow are already in place. And lucky for
3 Biotech Stocks With Big News Coming
Clinical trial data and FDA decisions can cause biotech stocks to pop or drop, and that makes it critical for biotech investors to keep a close eye on Flexion Therapeutics (NASDAQ: FLXN), Keryx
These 2 Marijuana Stocks Moved in Completely Opposite Directions Last Week
In case you haven't noticed, marijuana stocks have been nothing short of unstoppable over the past year. As of a few weeks prior, the average marijuana stock with a market cap in excess of $200
Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand
Illumina Inc. (NASDAQ: ILMN) started out 2017 on a positive note by beating its first-quarter revenue guidance and coming in at the upper end of its earnings guidance. However, there were a few
Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand
Illumina Inc. (NASDAQ: ILMN) started out 2017 on a positive note by beating its first-quarter revenue guidance and coming in at the upper end of its earnings guidance. However, there were a few
Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand
Illumina Inc. (NASDAQ: ILMN) started out 2017 on a positive note by beating its first-quarter revenue guidance and coming in at the upper end of its earnings guidance. However, there were a few